AMD

OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference

Thursday, October 21, 2021 - 5:00pm

SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc .

Key Points: 
  • SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc .
  • (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Companys management will hold one-on-one partnering meetings at BIO-Europe Digital 2021, being held virtually October 25-28, 2021.
  • The Companys core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

AMD Ryzen™ Threadripper™ PRO Processors Selected for Next-Generation NVIDIA GeForce NOW Cloud Gaming Platform

Thursday, October 21, 2021 - 2:00pm

SANTA CLARA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today announced Ryzen Threadripper PRO processors will help power the new GeForce NOW RTX 3080 membership tier from NVIDIA.

Key Points: 
  • SANTA CLARA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) today announced Ryzen Threadripper PRO processors will help power the new GeForce NOW RTX 3080 membership tier from NVIDIA.
  • Driven by AMD Ryzen Threadripper PRO processors, the new GeForce NOW RTX 3080 membership gives next-generation cloud gaming experiences to players everywhere.
  • NVIDIAs GeForce SuperPods harness the class-leading performance of AMD Ryzen Threadripper PRO with unparalleled core counts and high-frequency clock speeds to support over 39 petaflops of graphics performance.
  • Working with NVIDIA, it is clear that the expansive feature set of Ryzen Threadripper PRO is the perfect platform to power their next-generation cloud gaming experience.

NVIDIA Introduces the Next Generation in Cloud Gaming

Thursday, October 21, 2021 - 2:00pm

SANTA CLARA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NVIDIA today announced its next-generation cloud gaming platform delivering GeForce RTX 3080-class gaming on GeForce NOW available exclusively in a new, high-performance membership tier.

Key Points: 
  • SANTA CLARA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NVIDIA today announced its next-generation cloud gaming platform delivering GeForce RTX 3080-class gaming on GeForce NOW available exclusively in a new, high-performance membership tier.
  • Each cloud GeForce NOW SuperPOD consists of over 1,000 GPUs that deliver more than 39 petaflops of graphics horsepower.
  • The lines between gaming, sport, art and social are increasingly blurred in video games, said NVIDIA founder and CEO Jensen Huang.
  • While we continue to drive the most advanced gaming technology with GeForce RTX, we have dedicated the past decade to refining and expanding GeForce NOW cloud gaming to bring the best gaming platform to anyone with a computer.

RAVE Computer to Showcase the New Varjo Aero Powered by RAVE RenderBEAST Compute at Oakland University’s Augmented Reality Center

Thursday, October 21, 2021 - 1:00pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211021005406/en/
    RAVE Computer to Showcase the New Varjo Aero Powered by RAVE RenderBEAST Compute (Photo: Business Wire)
    The new Varjo Aero features 35 pixels per degree, advanced ergonomics, active cooling, and crystal-clear variable resolution aspheric lenses which eliminate ghost rays and reflections.
  • The Aero HMD is the best option for anyone needing a high-resolution immersive experience on a budget, shared Devin Fowler, RAVE Product Development.
  • Weve optimized our Varjo-ready RenderBEAST specifically for the new Aero headset to provide the best user experience possible.
  • Our elite partnership with RAVE Computer goes beyond hardware, said Tristan Cotter, GM of Varjo North America.

LayerHost.com, Now Offering AMD EPYC Dedicated Servers, Delivering Superior Performance

Wednesday, October 20, 2021 - 4:00pm

Built on the company's Zen architecture and with a security-forward design, this upgrade for LayerHost will provide customers with higher performance, less latency, and reliably safe computing on our AMD EPYC servers.

Key Points: 
  • Built on the company's Zen architecture and with a security-forward design, this upgrade for LayerHost will provide customers with higher performance, less latency, and reliably safe computing on our AMD EPYC servers.
  • "The upgrade to AMD EPYC CPUs will provide our clients with state-of-the-art speed and performance with industry-leading security."
  • For businesses seeking server processing that can keep up with changing technology, LayerHost and AMD EPYC are the answer.
  • The move to AMD EPYC processors allows us to deliver that and more to our customers who want dedicated servers that can keep up with their ever-evolving computing needs.

OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A

Wednesday, October 20, 2021 - 1:30pm

OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg).

Key Points: 
  • OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg).
  • It allows suppression of HBV replication and has been confirmed to be functional against all major HBV genotypes and subtypes.
  • Active pharmaceutical ingredient (API) production of OLX703A for preclinical and clinical studies is currently underway with LGC BioSearch Technologies.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference

Tuesday, October 19, 2021 - 1:34pm

The 2 nd Annual Dry AMD Therapeutic Development conference requires registration for attendance.

Key Points: 
  • The 2 nd Annual Dry AMD Therapeutic Development conference requires registration for attendance.
  • OCU410 is the second drug candidate from Ocugens Modifier Gene Therapy Platform, which is expected to enter clinical trials in 2022.
  • Ocugen recently announced a collaboration with CanSinoBIO for the chemistry, manufacturing, and controls (CMC) development and manufacture of clinical supplies of OCU410 to advance the program.
  • Dry AMD is the most prevalent, chronic form of age-related macular degeneration, accounting for about 90 percent of all cases.

AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit

Tuesday, October 19, 2021 - 1:00pm

Ms. Washer will discuss the potential to leverage AAV gene therapy to treat dry-age related macular degeneration (AMD), including the relevance of expressing complement factor H as a therapeutic approach.

Key Points: 
  • Ms. Washer will discuss the potential to leverage AAV gene therapy to treat dry-age related macular degeneration (AMD), including the relevance of expressing complement factor H as a therapeutic approach.
  • She will also showcase AGTCs approach to developing an optimized vector construct for the treatment of dry-AMD.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • Forward-looking statements include information concerning preclinical and clinical product development and regulatory progress, potential growth opportunities, and potential market opportunities.

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

Tuesday, October 19, 2021 - 12:00pm

LOS ALTOS, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported in multiple oral presentations at the 2nd Annual Dry AMD Therapeutic Development Summit. Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD. Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals. The conference, which is being conducted in a virtual format, is being held October 19-21, 2021.

Key Points: 
  • Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD.
  • Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals.
  • The company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter.
  • Study results demonstrated that animals treated with RT011 experienced decreasing levels of retinal damage with increasing tissue concentrations of RT011.

Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit

Tuesday, October 19, 2021 - 12:00pm

Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).

Key Points: 
  • Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD).
  • GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy.
  • Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.
  • The information that Gemini posts on these channels and websites could be deemed to be material information.